<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with OASIS Tables v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing-oasis-article1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName taylorfrancis2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncoimmunology</journal-id><journal-id journal-id-type="iso-abbrev">Oncoimmunology</journal-id><journal-id journal-id-type="pmc">KONI</journal-id><journal-title-group><journal-title>Oncoimmunology</journal-title></journal-title-group><issn pub-type="ppub">2162-4011</issn><issn pub-type="epub">2162-402X</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4839358</article-id><article-id pub-id-type="publisher-id">1072675</article-id><article-id pub-id-type="doi">10.1080/2162402X.2015.1072675</article-id><article-categories><subj-group subj-group-type="heading"><subject>Author's View</subject></subj-group></article-categories><title-group><article-title><italic>POLE</italic> proofreading mutation, immune response and prognosis in endometrial cancer</article-title><alt-title alt-title-type="running-authors">I. C. VAN GOOL et&#x000a0;al.</alt-title><alt-title alt-title-type="running-title">OncoImmunology</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van Gool</surname><given-names>Inge C.</given-names></name><xref ref-type="aff" rid="af0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bosse</surname><given-names>Tjalling</given-names></name><xref ref-type="aff" rid="af0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Church</surname><given-names>David N.</given-names></name><xref ref-type="aff" rid="af0002"><sup>b</sup></xref><xref ref-type="corresp" rid="an0001"/></contrib><aff id="af0001"><label>a</label><institution>Department of Pathology, Leiden University Medical Center</institution>, Leiden, <country>the Netherlands</country></aff><aff id="af0002"><label>b</label><institution>Molecular and Population Genetics Laboratory, The Wellcome Trust Centre for Human Genetics, University of Oxford</institution>, Oxford, <country>UK</country></aff></contrib-group><author-notes><corresp id="an0001">David N. Church; <email xlink:href="dchurch@well.ox.ac.uk">dchurch@well.ox.ac.uk</email></corresp></author-notes><pub-date pub-type="collection"><month>3</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>12</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>8</month><year>2015</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the							<pub-date pub-type="epub"/>. --><volume>5</volume><issue>3</issue><elocation-id seq="9">e1072675</elocation-id><history><date date-type="received"><day>8</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>8</day><month>7</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="description"> &#x000a9; Inge C. van Gool, Tjalling Bosse, and David N. Church <copyright-statement>--><copyright-statement>&#x000a9; 2016 The Author(s). Published with license by Taylor &#x00026; Francis Group, LLC</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">http://creativecommons.org/licenses/by/3.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="koni-05-03-1072675.pdf"/><abstract><title>ABSTRACT</title><p>Endometrial cancers (ECs) with <italic>POLE</italic> proofreading mutations are typified by ultramutation and excellent prognosis. We investigated whether these were related, and found that <italic>POLE</italic>-mutant ECs display a robust T cell response that corresponds to an enrichment of antigenic tumor neopeptides. Enhanced immunogenicity may explain the favorable outcome of <italic>POLE</italic>-mutant ECs.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>DNA polymerase &#x003b5;</kwd><kwd><italic>POLE</italic></kwd><kwd>ultramutation</kwd><kwd>neopeptide</kwd></kwd-group><counts><fig-count count="1"/><table-count count="0"/><ref-count count="10"/><page-count count="3"/></counts></article-meta></front><body><p>The proofreading exonuclease activity intrinsic to the replicative DNA polymerases epsilon and delta (Pols &#x003b5; and &#x003b4;) is essential to maintain fidelity of DNA replication and prevent mutagenesis. While a role for defective polymerase proofreading in human cancer has long been postulated, this has only recently been confirmed, with the demonstration that germline mutations in the exonuclease domains of <italic>POLE</italic> and <italic>POLD1</italic> (which encode the principal subunits of Pols &#x003b5; and &#x003b4; respectively) predispose to cancer.<xref rid="cit0001" ref-type="bibr"><sup>1</sup></xref> Subsequently, we and others have shown that somatic <italic>POLE</italic> proofreading mutations occur in 7&#x02013;12% ECs,<xref rid="cit0002" ref-type="bibr"><sup>2,3</sup></xref> 1&#x02013;2% colorectal cancers (CRCs), as well as cancers of the brain, stomach and pancreas (TCGA unpublished, http://www.cbioportal.org, accessed June 2015). In keeping with the essential contribution of polymerase proofreading to replication fidelity, <italic>POLE</italic> proofreading-mutant ECs are ultramutated.<xref rid="cit0003" ref-type="bibr"><sup>3</sup></xref> However, perhaps less predictably, they also have an excellent prognosis.<xref rid="cit0003" ref-type="bibr"><sup>3,4</sup></xref> We hypothesized that these two characteristics may be related&#x02014;more specifically, that tumor neopeptides caused by ultramutation may stimulate a cytolytic immune response, analogous to previous observations in hypermutated mismatch repair-deficient CRCs.<xref rid="cit0005" ref-type="bibr"><sup>5</sup></xref> In a recent study,<xref rid="cit0006" ref-type="bibr"><sup>6</sup></xref> we investigated this in two large EC cohorts.</p><p>Following the observation that <italic>POLE</italic> proofreading-mutants had a higher density of tumor-infiltrating lymphocytes (TILs) than other ECs, we confirmed that this represented a CD8<sup>+</sup> cytotoxic T cell infiltrate likely to be capable of cytolytic activity, as evidenced by co-staining for the activation marker TIA-1. Consistent with these data, examination of RNAseq data from the independent TCGA EC series confirmed significant enrichment for immune-related pathways and a highly specific 200-gene tumor T cell infiltration signature in <italic>POLE</italic> proofreading-mutant ECs. This analysis also demonstrated that <italic>POLE</italic>-mutant tumors displayed significantly increased expression of CD8A (gene) and other T cell cytotoxic differentiation and effector markers known to predict favorable outcome in cancer,<xref rid="cit0007" ref-type="bibr"><sup>7</sup></xref> including T-bet, Eomes, IFN&#x003b3;, perforin and granzymes B, H, K and M. Using a bio-informatic approach to investigate the possible contribution of antigenic tumor neopeptides to the antitumor immune response, we found that <italic>POLE</italic> proofreading-mutant ECs were predicted to display substantially more antigenic peptides than other ECs, providing a potential explanation for our findings.</p><p>Taken together, our data suggest that enhanced immunogenicity contributes to the excellent prognosis of <italic>POLE</italic> proofreading-mutant ECs, and are concordant with a recent study, which showed that dendritic cells pulsed by <italic>POLE</italic>-mutant tumor lysates stimulated greater CD4<sup>+</sup> and CD8<sup>+</sup> cell proliferation than those pulsed by ECs lacking <italic>POLE</italic> mutations.<xref rid="cit0008" ref-type="bibr"><sup>8</sup></xref> However, this begs the question of why <italic>POLE-</italic>mutant ECs are not eliminated by this enhanced cytotoxic T cell response? We found no evidence of an increased frequency of loss of HLA class I protein expression in <italic>POLE</italic>-mutant ECs, and functional mutations in the antigen presentation machinery also appeared relatively uncommon (2 of 18 cases). In contrast, we found striking increases in the expression of immunosuppressive checkpoint molecules and Treg markers, including LAG3, TIM-3, TIGIT, PD1, CTLA4 and FOXP3, in <italic>POLE</italic>-mutant ECs, suggesting that this may be the principal mechanism of immune evasion in these tumors.</p><p>In short, our data suggest that <italic>POLE</italic> proofreading-mutant ECs evoke a striking antitumor immune response, which is likely to contribute at least partly to their excellent prognosis (<xref ref-type="fig" rid="f0001">Fig. 1</xref>). In addition to validating our results in further independent EC series, it will be important to determine whether an enhanced cytotoxic T cell reaction also occurs in other <italic>POLE</italic> proofreading-mutant cancers. Interestingly, recent data suggest this may be the case in glioblastomas.<xref rid="cit0009" ref-type="bibr"><sup>9</sup></xref> Given the association between benefit from immune checkpoint inhibitors and tumor mutation burden,<xref rid="cit0010" ref-type="bibr"><sup>10</sup></xref> our study also suggests that the few patients with advanced or recurrent <italic>POLE</italic> proofreading-mutant cancers may be promising candidates for these agents. Finally, a pressing question is why some <italic>POLE</italic>-mutant tumors do not appear to stimulate as potent an immune reaction as others? Is it simply that these tumors are less mutated? Or do they harbor novel mechanisms of immune escape? Thus, while much remains unknown, further study of <italic>POLE</italic>-mutant cancers may provide insights into antitumor immune response and evasion that are generalizable more broadly, with potential benefits for a wide range of cancer patients.</p></body><back><sec id="s0002" sec-type="other"><title>Disclosure of potential conflicts of interest</title><p>No potential conflict of interest was disclosed.
<fig id="f0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Possible mechanism linking <italic>POLE</italic> proofreading mutation, immune response and favorable endometrial cancer prognosis. <italic>POLE</italic> encodes the catalytic and proofreading subunit of DNA polymerase &#x003b5; (Pol &#x003b5;), the leading strand replicase in humans. Cancer-associated <italic>POLE</italic> exonuclease domain mutations perturb proofreading activity, resulting in tumor ultramutation. Enhanced presentation of mutated antigenic neopeptides stimulates both a cytolytic T cell response and upregulation of immunosuppressive checkpoints; however, increased effector cytokine expression (not shown) suggests that the T cell response is functional and at least partly contributes to the favorable prognosis of <italic>POLE</italic> proofreading-mutant endometrial cancers.</p></caption><graphic specific-use="web-only" xlink:href="koni-05-03-1072675-g001"/></fig>
</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palles</surname><given-names>C</given-names></name>, <name><surname>Cazier</surname><given-names>JB</given-names></name>, <name><surname>Howarth</surname><given-names>KM</given-names></name>, <name><surname>Domingo</surname><given-names>E</given-names></name>, <name><surname>Jones</surname><given-names>AM</given-names></name>, <name><surname>Broderick</surname><given-names>P</given-names></name>, <name><surname>Kemp</surname><given-names>Z</given-names></name>, <name><surname>Spain</surname><given-names>SL</given-names></name>, <name><surname>Almeida</surname><given-names>EG</given-names></name>, <name><surname>Salguero</surname><given-names>I</given-names></name> et&#x000a0;al.</person-group>
<article-title>Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas</article-title>. <source>Nat Genet</source>
<year>2013</year>; <volume>45</volume>(<issue>2</issue>):<fpage>136</fpage>-<lpage>44</lpage>; PMID:23263490; http://dx.doi.org/23528559<pub-id pub-id-type="doi">10.1038/ng.2503</pub-id>.<pub-id pub-id-type="pmid">23263490</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Church</surname><given-names>DN</given-names></name>, <name><surname>Briggs</surname><given-names>SE</given-names></name>, <name><surname>Palles</surname><given-names>C</given-names></name>, <name><surname>Domingo</surname><given-names>E</given-names></name>, <name><surname>Kearsey</surname><given-names>SJ</given-names></name>, <name><surname>Grimes</surname><given-names>JM</given-names></name>, <name><surname>Gorman</surname><given-names>M</given-names></name>, <name><surname>Martin</surname><given-names>L</given-names></name>, <name><surname>Howarth</surname><given-names>KM</given-names></name>, <name><surname>Hodgson</surname><given-names>SV</given-names></name> et&#x000a0;al.</person-group>
<article-title>DNA polymerase epsilon and delta exonuclease domain mutations in endometrial cancer</article-title>. <source>Hum Mol Genet</source>
<year>2013</year>; <volume>22</volume>:<fpage>2820</fpage>-<lpage>8</lpage>; PMID:23528559; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/hmg/ddt131</pub-id>.<?supplied-pmid 23528559?><pub-id pub-id-type="pmid">23528559</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The Cancer Genome Atlas</collab></person-group>
<article-title>Integrated genomic characterization of endometrial carcinoma</article-title>. <source>Nature</source>
<year>2013</year>; <volume>497</volume>(<issue>7447</issue>):<fpage>67</fpage>-<lpage>73</lpage>; PMID:23636398; http://dx.doi.org/20142816<pub-id pub-id-type="doi">10.1038/nature12113</pub-id>.<pub-id pub-id-type="pmid">23636398</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Church</surname><given-names>DN</given-names></name>, <name><surname>Stelloo</surname><given-names>E</given-names></name>, <name><surname>Nout</surname><given-names>R</given-names></name>, <name><surname>Valtcheva</surname><given-names>N</given-names></name>, <name><surname>Depreeuw</surname><given-names>J</given-names></name>, <name><surname>ter Haar</surname><given-names>N</given-names></name>, <name><surname>Noske</surname><given-names>A</given-names></name>, <name><surname>Amant</surname><given-names>F</given-names></name>, <name><surname>Tomlinson</surname><given-names>IPM</given-names></name>, <name><surname>Wild</surname><given-names>PJ</given-names></name> et&#x000a0;al.</person-group>
<article-title>Prognostic significance of POLE proofreading mutations in endometrial cancer</article-title>. <source>J Natl Cancer Inst</source>
<year>2015</year>; <volume>107</volume>(<issue>1</issue>):<fpage>402.5</fpage>; PMID:25505230; http://dx.doi.org/20142816<pub-id pub-id-type="doi">10.1093/jnci/dju402</pub-id>.<pub-id pub-id-type="pmid">25505230</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilar</surname><given-names>E</given-names></name>, <name><surname>Gruber</surname><given-names>SB</given-names></name></person-group>. <article-title>Microsatellite instability in colorectal cancer&#x02014;the stable evidence</article-title>. <source>Nat Rev Clin Oncol</source>
<year>2010</year>; <volume>7</volume>:<fpage>153</fpage>-<lpage>62</lpage>; PMID:20142816; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nrclinonc.2009.237</pub-id><?supplied-pmid 20142816?><pub-id pub-id-type="pmid">20142816</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Gool</surname><given-names>IC</given-names></name>, <name><surname>Eggink</surname><given-names>FA</given-names></name>, <name><surname>Freeman-Mills</surname><given-names>L</given-names></name>, <name><surname>Stelloo</surname><given-names>E</given-names></name>, <name><surname>Marchi</surname><given-names>E</given-names></name>, <name><surname>de Bruyn</surname><given-names>M</given-names></name>, <name><surname>Palles</surname><given-names>C</given-names></name>, <name><surname>Nout</surname><given-names>RA</given-names></name>, <name><surname>de Kroon</surname><given-names>CD</given-names></name>, <name><surname>Osse</surname><given-names>EM</given-names></name> et&#x000a0;al.</person-group>
<article-title>POLE Proofreading Mutations Elicit an Antitumour Immune Response in Endometrial Cancer</article-title>. <source>Clin Cancer Res</source> Advance Online Publication <year>2015</year>; <volume>21</volume>(<issue>14</issue>):<fpage>3347</fpage>-<lpage>55</lpage>; PMID:25878334; http://dx.doi.org/24138885<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-0057</pub-id><pub-id pub-id-type="pmid">25878334</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bindea</surname><given-names>G</given-names></name>, <name><surname>Mlecnik</surname><given-names>B</given-names></name>, <name><surname>Tosolini</surname><given-names>M</given-names></name>, <name><surname>Kirilovsky</surname><given-names>A</given-names></name>, <name><surname>Waldner</surname><given-names>M</given-names></name>, <name><surname>Obenauf</surname><given-names>AC</given-names></name>, <name><surname>Angell</surname><given-names>H</given-names></name>, <name><surname>Fredriksen</surname><given-names>T</given-names></name>, <name><surname>Lafontaine</surname><given-names>L</given-names></name>, <name><surname>Berger</surname><given-names>A</given-names></name> et&#x000a0;al.</person-group>
<article-title>Spatiotemporal dynamics of intratumoural immune cells reveal the immune landscape in human cancer</article-title>. <source>Immunity</source>
<year>2013</year>; <volume>39</volume>:<fpage>782</fpage>-<lpage>95</lpage>; PMID:24138885; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.immuni.2013.10.003</pub-id>.<?supplied-pmid 24138885?><pub-id pub-id-type="pmid">24138885</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellone</surname><given-names>S</given-names></name>, <name><surname>Centritto</surname><given-names>F</given-names></name>, <name><surname>Black</surname><given-names>J</given-names></name>, <name><surname>Schwab</surname><given-names>C</given-names></name>, <name><surname>English</surname><given-names>D</given-names></name>, <name><surname>Cocco</surname><given-names>E</given-names></name>, <name><surname>Lopez</surname><given-names>S</given-names></name>, <name><surname>Bonazzoli</surname><given-names>E</given-names></name>, <name><surname>Predolini</surname><given-names>F</given-names></name>, <name><surname>Ferrari</surname><given-names>F</given-names></name> et&#x000a0;al.</person-group>
<article-title>Polymerase epsilon (POLE) ultra-mutated tumours induce robust tumour-specific CD4+ T cell responses in endometrial cancer patients</article-title>. <source>Gynecol Oncol</source>
<year>2015</year>; <volume>138</volume>(<issue>1</issue>):<fpage>11</fpage>-<lpage>7</lpage>; PMID:25931171; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.ygyno.2015.04.027</pub-id>.<pub-id pub-id-type="pmid">25931171</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erson-Omay</surname><given-names>EZ</given-names></name>, <name><surname>Caglayan</surname><given-names>AO</given-names></name>, <name><surname>Schultz</surname><given-names>N</given-names></name>, <name><surname>Weinhold</surname><given-names>N</given-names></name>, <name><surname>Omay</surname><given-names>SB</given-names></name>, <name><surname>Ozduman</surname><given-names>K</given-names></name>, <name><surname>Koksal</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Serin Harmanci</surname><given-names>A</given-names></name>, <name><surname>Clark</surname><given-names>V</given-names></name> et&#x000a0;al.</person-group>
<article-title>Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis</article-title>. <source>Neuro Oncol</source>. Advance Online Publication <year>2015</year>; 17(10):1356-64; PMID:25740784; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/neuonc/nov027</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname><given-names>A</given-names></name>, <name><surname>Makarov</surname><given-names>V</given-names></name>, <name><surname>Merghoub</surname><given-names>T</given-names></name>, <name><surname>Yuan</surname><given-names>J</given-names></name>, <name><surname>Zaretsky</surname><given-names>JM</given-names></name>, <name><surname>Desrichard</surname><given-names>A</given-names></name>, <name><surname>Walsh</surname><given-names>LA</given-names></name>, <name><surname>Postow</surname><given-names>MA</given-names></name>, <name><surname>Wong</surname><given-names>P</given-names></name>, <name><surname>Ho</surname><given-names>TS</given-names></name> et&#x000a0;al.</person-group>
<article-title>Genetic basis for clinical response to CTLA-4 blockade in melanoma</article-title>. <source>N Engl J Med</source>
<year>2014</year>; <volume>371</volume>(<issue>23</issue>):<fpage>2189</fpage>-<lpage>99</lpage>; PMID:25409260; http://dx.doi.org/<pub-id pub-id-type="doi">10.1056/NEJMoa1406498</pub-id><pub-id pub-id-type="pmid">25409260</pub-id></mixed-citation></ref></ref-list></back></article>